Irreversible electroporation for unresectable hepatocellular carcinoma: Initial experience and review of safety and outcomes

Technology in Cancer Research and Treatment

Volumn 12, Issue 3, 2013, Pages 233-241

  Cheung, W ^a   Kavnoudias, H ^a   Roberts, S ^a,b   Szkandera, B ^a   Kemp, W ^a   Thomson, K R ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Hepatocellular carcinoma; Local tumour ablation

Indexed keywords

ANALGESIC AGENT; MORPHINE;

AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS FREE SURVIVAL; ELECTRODE; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MALE; MINIMAL RESIDUAL DISEASE; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; ULTRASOUND THERAPY; URETHRAL CATHETERIZATION; URINE RETENTION;

EID: 84877135188     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.7785/tcrt.2012.500317     Document Type: Article

References (28)

1. El-Serag, H. B. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastoenterol 35, S72-8 (2002). DOI: 10.1097/00004836-200211002-00002
2. Robotin, M. C., George, J., Supramaniam, R., Sitas, F., Penman, A. G. Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? MJA 188, 363-365 (2008). DOI: 10.1111/j.1753-6405.2008.00176.x
3. Alam, M., Robotin, M., Baker, D. Epidemiology of primary liver cancer. Cancerforum 2009, 33 (2009).
4. Roberts, S. K., Kemp, W. Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: change in epidemiology and clinical presentation. J Gastroenterol Hepatol 22, 191-196 (2007). DOI: 10.1111/j.1440-1746.2006.04459.x
5. Kanwal, F., Hoang, T., Kramer, J. R., Asch, S. M., Goetz, M. B., Zeringue, A., Richardson, P., El-Serag, H. B. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterol 140, 1182-88 (2011). DOI: 10.1053/ j.gastro.2010.12.032
6. Rubinsky, B. Irreversible electroporation in medicine. Technol Cancer Res Treat 6, 255-260 (2007).
7. Mir, L. M., Glass, L. F., Sersa, G., Teissié, J., Domenge, C., Miklavcic, D., Jaroszeski, M. J., Orlowski, S., Reintgen, D. S., Rudolf, Z., Belehradek, M., Gilbert, R., Rols, M. P., Belehradek, J. Jr, Bachaud, J. M., DeConti, R., Stabuc, B., Cemazar, M., Coninx, P., Heller, R. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77, 2336-42 (1998). DOI: 10.1038/ bjc.1998.388
8. Sersa, G., Miklavcic, D., Cemazar, M., Rudolf, Z., Pucihar, G., Snoj, M. Electrochemotherapy in treatment of tumours. EJSO 34, 232-240 (2008). DOI: 10.1016/j.ejso.2007.05.016
9. Testori, A., Tosti, G., Martinoli, C., Spadola, G., Cataldo, F., Verrecchia, F., Baldini, F., Mosconi, M., Soteldo, J., Tedeschi, I., Passoni, C., Pari, C., Di Pietro, A., Ferruchi, P. F. Electorchemotherapy for cutaneous and subcutaneous tumour lesions: a novel therapeutic approach. Dermatol Ther 23, 651-661 (2010). DOI: 10.1111/ j.1529-8019.2010.01370.x
10. Marty, M., Sersa, G., Garbay, J. R., Gehl, J., Collins, C. G., Snoj, M., Billard, V., Geertsen, P. F., Larkin, J. O., Miklavcic, D., Pavlovic, I., Paulin-Kosir, S. M., Cemazar, M., Morsli, N., Soden, D. M., Rudolf, Z. Robert, C., O'Sullivan, G. C., Mir, L. M. Electrochemotherapy An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Euro J Cancer Suppl 4, 3-13 (2006). DOI: 10.1016/ j.ejcsup.2006.08.002
11. Edhemovic, I., Gadzijev, E. M., Brecelj, E., Miklavcic, D., Kos, B., Zupanic, A., Mali, B., Jarm, T., Pavliha, D., Marcan, M., Gasljevic, G., Gorjup, V., Music, M., PecnikVavpotic, T., Cemazar, M., Snoj, M., Sersa, G. Electochemotherapy: a new technological approach in treatment of metastases in liver. Technol in Can Res and Treat 10, 475-485 (2011).
12. Lee, E. W., Loh, C. T., Kee, S. T. Imaging guided percutaneous irreversible electroporation: ultrasound and immunological correlation. Technol Cancer Res Treat 6, 287-294 (2007).
13. Onik, E., Rubinsky, B., Mikus, P. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 6, 295-300 (2007).
14. Lee, E. W., Chen, C., Prieto, V. E., Dry, S. M., Loh, C. T., Kee, S. T. Advanced hepatic ablation technique for creating com- plete cell death: irreversible electroporation. Radiology 255, 426-433 (2010). DOI: 10.1038/sj.bjc.6604168
15. Thomson, K. R., Cheung, W., Ellis, S. J., Federman, D., Kavnoudias, H., Loader-Oliver, D., Roberts, S., Evans, P., Ball, C., Haydon, A. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22, 611-621 (2011). DOI: 10.1016/j.jvir.2010.12.014
16. Ball, C., Thomson, K. R., Kavnoudias, H. Irreversible electroporation: a new challenge in "out of operation theatre" anaesthesia. Irreversible electroporation: a new challenge in "out of operation theatre" anaesthesia. Anaesth Analg 10, 1305-1309 (2010). DOI: 10.1213/ ANE.0b013e3181d27b30
17. Bruix, J., Sherman, M. Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005). DOI: 10.1002/hep.20933
18. Lencioni, R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 52, 762-773 (2010). DOI: 10.1002/hep.23725
19. Livraghi, T. Radiofrequency ablation, PEIT and TACE for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 10, 67-76 (2003). DOI: 10.1007/s10534-002-0714-y
20. Cho, Y. K., Kim, J. K., Kim, M. Y., Rhim, H., Han, J. K. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49, 453-459 (2009). DOI: 10.1002/hep.22648
21. Lau, W., Lai, E. The current role of radiofrequency ablation in the management of hepatocellular carcinoma a systemic review. Annals of Surgery 249, 20-25 (2009). DOI: 10.1097/SLA.0b013e31818eec29
22. N'Kontchou, G., Mahamoudi, A., Aout, M., Ganne-Carrié, N., rando, V., Coderc, E., Vicaut, E., Trinchet, J. C., Sellier, N., Beaugrand, M., Seror, O. Radiofrequency ablation of hepatocellular carcinoma: longterm results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50, 1475-1483 (2009). DOI: 10.1002/hep.23181
23. Bouza, C., López-Cuadrado, T., Alcázar, R., Saz-Parkinson, Z., Amate, J. M. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 9, 31 (2009). DOI: 10.1186/1471-230X-9-31
24. Lencioni, R. A., Allgaier, H. P., Cioni, D., Olschewski, M., Deibert, P., Crocetti, L., Frings, H., Laubenberger, J., Zuber, I., Blum, H. E., Bartolozzi, C. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228, 235-240 (2003). DOI: 10.1148/radiol.2281020718
25. Livraghi, T., Meloni, F., Di Stasi, M., Rolle, E., Solbiati, L., Tinelli, C., Rossi, S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47, 82-89 (2008). DOI: 10.1002/hep.21933
26. Teratani, T., Yoshida, H., Shiina, S., Obi, S., Sato, S., Tateishi, R., Mine, N., Kondo, Y., Kawabe, T., Omata, M. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 43, 1101-1108 (2006). DOI: 10.1002/hep.21164
27. Loh, K. B., Bux, S. I., Abdullah, B. J. J., Mokhtar, R. A. R., Mohamed, R. Hemorrhagic cardiac tamponade: rare complication of radiofrequency ablation of hepatocellular carcinoma. Korean J of Radiol 13, 643-647 (2012). DOI: 10.3348/kjr.2012.13.5.643
28. Sersa, G., Jarm, T., Kotnik, T., Coer, A., Podkrajsek, M., Sentjurc, M., Miklavci, D., Kadivec, M., Kranjc, S., Secerov, A., Cemazar, M. Vascular disruption action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Br J Cancer 98, 388-398 (2008). DOI: 10.1038/sj.bjc.66041